The Australian Leukaemia Study Group (ALSG) investigated whether G-CSF would accelerate haemopoietic recovery after induction treatment for acute myeloid leukaemia (AML) intensified with high-dose cytarabine, and therefore improve response rates and survival. Patients were randomised to receive lenograstim (glycosylated recombinant human G-CSF) 5 g per kg body weight subcutaneously daily from day 8 after starting chemotherapy, or no cytokine, following chemotherapy with cytarabine 3 g/m 2 every 12 h on days 1, 3, 5, and 7, together with idarubicin 9 or 12 mg/m 2 on days 1, 2, and 3, plus etoposide 75 mg/m 2 on days 1 to 7 inclusive. Patients had untreated AML, and were aged 16 to 60 years. Overall, 54 evaluable patients were randomised to receive lenograstim and 58 to no cytokine. Patients in the lenograstim arm had a significantly shorter duration of neutropenia Ͻ0.5 × 10 9 /l compared to patients in the no cytokine arm (median 18 vs 22 days; P = 0.0005), and also shorter duration of total leucopenia Ͻ1.0 × 10 9 /l (17 vs 19 days; P = 0.0002), as well as a reduction in duration of treatment with therapeutic intravenous antibiotics (20 vs 24 days; P = 0.015) and a trend to reduced number of days with fever Ͼ38.0°C (9 vs 12 days; P = 0.18). There were no differences between the two groups in platelet recovery, red cell or platelet transfusions, or non-haematological toxicities. For patients achieving CR after their first induction course, a reduction in the time to the start of the next course of therapy was observed in the lenograstim arm, from a median of 40.5 days to a median of 36 days (P = 0.082). The overall complete response rates to chemotherapy were similar, 81% in the lenograstim arm vs 75% for the no cytokine arm (P = 0.5), and there was no significant difference in the survival durations. We conclude that the granulopoietic stimulating effect of G-CSF is observed after induction therapy for AML intensified by highdose cytarabine, resulting in an improvement in a number of clinically important parameters with no major adverse effects. Leukemia (2001Leukemia ( ) 15, 1331Leukemia ( -1338 
Introduction
Severe neutropenia is a universal occurrence after induction chemotherapy for AML, due to the disease process itself and particularly to the myelosuppressive cytotoxic chemotherapy given to eradicate the disease. Neutropenia results in a high risk of bacterial and fungal infection, heavy requirements for antibiotic and supportive care, and prolonged hospitalization. Infection resulting from severe neutropenia is the most com- mon cause of death after induction treatment for AML. Prolonged neutropenia is a particular problem after intensified chemotherapy for AML, given to attempt to improve response rates by overcoming inherent leukaemic drug resistance. 1, 2 In the ALSG M4 protocol conducted by the Australian Leukaemia Study Group, there was greater myelotoxicity, with higher infection and early death rates, in the group of patients receiving treatment intensified with high-dose cytarabine (eight doses of 3 g/m
2 ) compared to patients treated with cytarabine at conventional doses. 2 Although responding patients treated on the high-dose cytarabine arm had superior leukaemia-free survival compared to those receiving conventional therapy, the potential survival benefit was reduced by the higher early toxic death rate in the high-dose group.
A reduction in infective deaths during neutropenia could substantially improve the response rate in AML, and might allow safer delivery of more intensive treatment, allowing the long-term effects of high-dose cytarabine to be evaluated in a higher proportion of patients. One potential mechanism for doing this is to shorten the duration of neutropenia after chemotherapy. This has been achieved after cytotoxic chemotherapy for a variety of cancers using myeloid growth factors, including the cytokines G-CSF, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-3.
3,4 AML has been an obvious further candidate for cytokine therapy, although concerns were raised about the expression of cytokine receptors on the leukaemic cells and the consequent risk of accelerating the growth of the disease if administered after completion of cytotoxic therapy. 5 Despite this, early studies were carried out in relapsed AML undergoing salvage treatment using G-CSF or GM-CSF, without evidence of leukaemic cell stimulation. 6 These reports documented the shortening of neutropenia with myeloid cytokines, but demonstrated conflicting findings on other clinical endpoints, such as rates of infection and early death, complete response rates and survival. Subsequently, a number of studies were performed on untreated newly diagnosed patients with AML, and the findings again confirmed the reduction in neutropenia in this setting. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Virtually all of the myeloid cytokine studies have been carried out using conventional doses of induction therapy for AML. There is therefore little information on whether the reduction in neutropenia observed would also occur if significantly more myelosuppressive chemotherapy was used, and if so, whether this would translate into reduced risk of infective deaths and improved survival following intensified therapy. In order to clarify this issue, the Australian Leukaemia Study Group incorporated a cytokine randomisation arm into its current high-dose chemotherapy protocol for adult AML. Newly diagnosed adult AML patients were equally randomised to receive lenograstim (glycosylated rhu-G-CSF) or no cytokine immediately following induction chemotherapy incorporating high-dose cytarabine. A sequential design of the study was used to examine duration of neutropenia as the primary endpoint.
Materials and methods

Patients
Patients were enrolled on to this study after registration on the ALSG M7 trial conducted by the Australian Leukaemia Study Group. This study opened in September 1995 and accrued from 18 hospitals in Australia. Eligibility criteria consisted of a morphological diagnosis of AML, no antecedent history of preleukaemia, haematological disorders or cancer, age 15 to 60 years, ECOG performance status 0-3, no co-existing major morbidity, and written informed consent to participate. Patients with FAB M3 acute promyelocytic leukaemia were excluded. A total of 114 eligible patients were enrolled between September 1995 and the closure of the cytokine randomisation in November 1997. On study characteristics are presented in Table 1 . The median age of the patients was 43 (range 15-60) years.
Treatment protocol
The chemotherapy protocol for the ALSG M7 trial was designed to assess the efficacy and tolerability of sequential courses of combination chemotherapy intensified with highdose cytarabine in the initial therapy of younger patients with de novo AML. The design incorporated a common initial course of therapy, termed ICE, using cytarabine 3 g/m 2 by 3-h intravenous infusion every 12 h on days 1, 3, 5, and 7 (total of eight doses), together with etoposide 75 mg/m 2 intravenously daily from days 1 to 7 inclusive, plus idarubicin 12 mg/m 2 intravenously on days 1, 2, and 3. Because of toxicity concerns, the dose of idarubicin was reduced to 9 mg/m 2 daily in November 1996; 44 (39%) of the 114 evaluable patients were randomised before and 70 (61%) after the dose reduction. Patients were evaluated for the outcome of this treatment course after 28 days by bone marrow examination. If not in complete remission, a second identical course of ICE was given at the discretion of the treating physician. Nonresponding patients were taken off study. Patients who achieved a complete response after one or two cycles of ICE were then randomised to receive an identical cycle of ICE as consolidation therapy, or to receive two courses of lower dose consolidation treatment, consisting of idarubicin 12 or 9 mg/m 2 on days 1 and 2, cytarabine 100 mg/m 2 by intravenous infusion on days 1 to 5 inclusive, plus etoposide 75 mg/m 2 on days 1 to 5 inclusive (IcE). Remission status was assessed by bone marrow examination after each consolidation course. No further chemotherapy was given after scheduled consolidation therapy, although allogeneic haematopoietic stem cell transplantation was permitted in first remission if a suitable donor was available. 
Cytokine randomisation
Patients registered on the ALSG M7 study were randomised prior to the initiation of treatment to receive lenograstim 5 g per kg body weight daily by subcutaneous injection from day 8, or to receive no cytokine. Lenograstim was to be continued until the absolute neutrophil count in the peripheral blood exceeded 2.0 × 10 9 /l on 3 successive days, or 5.0 × 10 9 /l on 1 day, or if there was evidence of residual leukaemia in the day 28 marrow biopsy. Responding patients randomised on the consolidation phase of the ALSG M7 trial all subsequently received lenograstim following the completion of either ICE or IcE courses, until the time of neutrophil recovery.
Data definitions
The duration of neutropenia was measured from the first day in the first cycle of chemotherapy with an absolute neutrophil count (ANC) Ͻ0.5 × 10 9 /l until the first day with an ANC у0.5 × 10 9 /l provided that this was sustained. The duration was censored if the last neutrophil count for the cycle was р0.5 × 10 9 /l. For patients with pre-existing neutropenia at the commencement of chemotherapy, the duration was calcu-lated from the date of commencement of chemotherapy. The durations of leucopenia and thrombocytopenia were defined similarly. In addition, the number of days with neutrophils р0.1 × 10 9 /l was also calculated, simply by adding up the number of individual days in the first cycle of chemotherapy that the neutrophil count was р0.1 × 10 9 /l, censoring if the last neutrophil count was Ͼ0.1 × 10 9 /l. For the days on which no blood count result was available, the estimated neutrophil count was interpolated. The median percentage of missing counts was 4.4% in the no cytokine arm and 2.4% in the lenograstim arm (P = 0.28).
Statistical analysis and study monitoring
Patients were randomised by telephoning the ALSG trial centre. Patients were stratified by participating centre prior to randomisation. Approximately equal numbers of patients were randomised to each arm in each centre. The method of randomisation was based on a biased coin design. 19 A triangular sequential design 20 was used to monitor the differences in the durations of neutropenia in induction to ensure that the trial would stop early if there was a striking advantage associated with lenograstim, or if there was no advantage, but continue to accrue patients if the advantage was only moderate, in which case more patients would be required to obtain a reliable estimate of the benefit. The interim analyses were planned to be conducted at approximately 6-monthly intervals. The stopping rules were designed using PEST3 software 21 using the sequential triangular design for survival data. The trial was designed to have a 90% power to pick up a clinically important decrease of 2 days in the duration of neutropenia associated with the lenograstim arm when tested at the 0.05 level of significance using a one-sided test.
The PEST3 software was also used to determine the significance of the difference in the durations of neutropenia between the two arms, and to provide the median unbiased estimate of the relative rate of recovery from neutropenia and its associated 95% confidence interval (CI). The cumulative distribution function of the duration of neutropenia was estimated for each randomisation arm using the Kaplan-Meier product-limit method. This method was also used to estimate the distribution of the durations of leucopenia and thrombocytopenia and the number of days with neutrophils р0.1 × 10 9 /l. The statistical significance of the difference between the two randomisation arms with respect to these was determined using the logrank test stratified by the time of therapy (before or after the date of changing the protocol dose of idarubicin from 12 mg/m 2 /day to 9 mg/m 2 /day). Complete response rates and other dichotomous variables have been compared between the treatment arms using the Fisher exact test, toxicity grades have been compared using the Cochran-Armitage test for trend, and all continuous variables which were not subject to censoring were compared using the Wilcoxon-Mann-Whitney test. All these tests were stratified by the time of therapy.
Survival duration was measured from the date of cytokine randomisation to the date of death, no matter what the cause. The data were analysed with a study close-out date of 1 September 2000. All survival data were censored at that date. Survival curves were estimated using the Kaplan-Meier method. The relative death rate (hazard ratio) was estimated using the Cox proportional hazards model, stratified by the time of therapy.
Leukemia
As specified in the protocol, one-sided P values were reported for the comparisons of neutropenia, fever, infections, antibiotic use and hospitalisation, as it was anticipated from past experience that the cytokine arm would be associated with a reduction in the duration of neutropenia and consequently lead to a reduction in the number of febrile days, the incidence of infections, the duration of antibiotic usage and the number of days in hospital. It was also anticipated prior to analysing the data that the cytokine arm would be associated with a reduction in the interval between the first and second courses due to a reduction in the delay between courses associated with lack of recovery of the bone marrow. In calculating the P-values and summary statistics for these associated variables, no adjustment has been made for the sequential nature of the trial. This could result in a bias in the estimates of these variables, 20 but will not affect any variables which are not correlated with the duration of neutropenia.
Median 
Methodology for comparing costs
The analysis of health care utilisation was restricted to the hospital setting. There were no important resource differences between the two randomisation arms with respect to induction chemotherapy doses, topical antibiotics, platelet transfusions, red blood cell transfusions and the number of 1-day admissions and outpatient visits. Thus cost comparisons were based solely on the costs of lenograstim, i.v. and oral antibiotics and inpatient bed-days. Costs were taken to be the costs of these items as at 1 March 2001. The analysis was limited to the first course of induction therapy as only five patients on the no cytokine arm and four patients on the lenograstim arm went on to receive a second induction course. Two randomised patients were excluded from the analysis, one who did not receive induction therapy, and one who died 2 days after commencing therapy. All costs have been reported in Australian dollars (A$) unless otherwise indicated.
As at 1 March 2001, lenograstim was available at a cost of $A128.36 for a 263 g vial through the Australian Pharmaceutical Benefits Schedule (PBS) as a 'section 100' item for highly specialised drugs, available through hospital pharmacies for out-patients. For each patient the daily dose and duration of lenograstim was recorded. This daily dose was used to obtain the cost per day. All intravenous (i.v.) and oral antibiotics given to the patients were recorded on the case record forms, together with their durations of administration. Standard doses were assumed and costs were based on hospital purchasing costs. The inpatient admission costs were based on the state hospital funding scheme used in New South Wales, whereby the reimbursement for each admission is based on the reason for admission, any relevant factors complicating the admission and the length of stay.
Results
The primary endpoint of the cytokine randomisation was to evaluate the effect of lenograstim on the duration of neutropenia after induction chemotherapy with the ICE protocol. Owing to the sequential design of this component of the ALSG M7 trial, the cytokine randomisation was closed in November 1997, when a significant difference between the two arms was detected on the third inspection of the data. A total of 114 eligible patients had been enrolled at that time; 54 had been randomised to receive lenograstim and 60 to no cytokine. Two patients, both on the no cytokine arm, were inevaluable with respect to the primary endpoint: one was withdrawn from the trial before commencing induction therapy due to pneumonia and one died from non-protocol-related causes 2 days after commencing induction. These patients are included in the response and survival comparisons. The remaining 112 randomised patients provided the basis of the toxicity comparisons.
The haematological recovery in the two groups of patients is presented in Table 2 . The main finding was a highly significant reduction in the duration of neutropenia (neutrophils Ͻ0.5 × 10 9 /l) in the lenograstim arm vs no cytokine arm (P = 0.0005 based on sequential analysis). The median unbiased estimate of the relative recovery rate of the neutrophil count for the lenograstin arm relative to the no cytokine arm was 2.6 (95% CI 1.5-4.2). Patients receiving lenograstim had a median duration of neutropenia Ͻ0.5 × 10 9 /l of 18 days Table 2 Haematological recovery after induction therapy in cytokine and no cytokine groups
No
Lenograstim P cytokine n = 54 n = 58 (95% CI 16-19 days), compared to 22 days (95% CI 20-23 days) in the no cytokine arm, while the number of days with neutrophil count р0.1 × 10 9 /l was 14 compared to 16 days in lenograstim vs no cytokine arms respectively (P = 0.0092) (Figures 1 and 2) . Lenograstim also shortened the duration of leucopenia by 2 days (P = 0.0002). In contrast, the median duration of thrombocytopenia was identical (22 days) in the lenograstim and no cytokine arms.
The effect of lenograstim on other treatment-related toxicities was also examined (Table 3) . Patients in the lenograstim arm had fewer days with fever exceeding 38.0°C than patients in the no cytokine arm (9 vs 12 days), but this did not reach statistical significance (P = 0.18). There was no difference, however, in the incidence of clinically or microbiologically documented infections, 69% for the no cytokine patients compared to 67% for those receiving lenograstim. Episodes of fever without documented cause were similar in the two groups, 21% in the no cytokine group compared to 26% in patients on lenograstim. The incidence of documented infections did not appear age-related, as 72% of 46 patients aged less than 40 years had documented infections (77% of patients on no cytokine vs 65% of lenograstim patients) compared with 66% of the 66 patients aged 40 to 60 years (63% of no cytokine group vs 68% of lenograstim group) (P = 0.54, Fisher's exact test). There was also no indication of a difference 
Figure 2
Days with neutrophils р0.1 × 10 9 /l. between these two age groups with respect to the association of lenograstim with documented infections (P = 0.42, exact test for homogeneity of odds ratio). The percentage of induction deaths associated with infections was also equivalent in both arms (9% vs 8% for the lenograstim and no cytokine arms, respectively). There was also no difference in nonhaematological toxicities; in particular, the rates of mucositis and gastrointestinal toxicity were comparable between the two groups of patients. The incidence of grade 3 and 4 stomatitis was 24% in the lenograstim arm compared to 21% in the no cytokine arm (P = 0.82), while grade 3 and 4 diarrhoea occurred in 30% of patients in the lenograstim arm compared to 38% in the no cytokine arm (P = 0.43). We also looked for an association between severe gastrointestinal toxicity and infection, and whether this might be influenced by lenograstim. However, no association was found. Documented infection rates for patients on the no cytokine arm who experienced grade 3 or 4 diarrhoea, stomatitis, or GIT toxicity, were respectively 81%, 67%, and 63%, while for the corresponding patients on the lenograstim arm the infection rates were 63% (P = 0.17), 62% (P = 0.56), and 75% (P = 0.59).
The use of lenograstim had an effect on the utilisation of a number of treatment resources. Days on therapeutic intravenous antibiotics were reduced in the lenograstim arm (20 vs 24 days; P = 0.015). Days on prophylactic oral antibiotics (recommended, but not mandated by the treatment protocol) were equivalent, 20.5 days for the no cytokine group vs 21.5 days for the lenograstim group. The duration of hospital stay for induction therapy was reduced from 29.5 days on the no cytokine arm to 28 days on the lenograstim arm (P = 0.21).
In order to determine the financial resource impact of the use of lenograstim during induction therapy, we carried out a costing analysis. Four patients on the no cytokine arm received lenograstim in their first course for the treatment of neutropenia. The mean cost per patient of lenograstim was A$120 on the no cytokine arm and A$3684 on the lenograstim arm. Lenograstim was associated with a mean saving of A$809 on i.v. antibiotics and A$59 on oral antibiotics. In addition, lenograstim was associated with a mean reduction of A$1203 in inpatient admission costs. Taking into account the cost of the cytokine, lenograstim was associated with a mean increase in cost of A $1494 (s.e. A$1942, P = 0.11, 95% CI a decrease of A$2354-an increase of A$5342). Based on an analysis of the logarithms of the costs, lenograstim was associated with an estimated 10% increase (95% CI a decrease of 6% to an increase of 29%) in the costs studied.
Leukemia
For patients responding to induction therapy, lenograstim resulted in a trend to shortening in the time to receive the next course of treatment. Patients on the lenograstim arm who achieved a response with the first course of ICE were able to start the subsequent consolidation course by median day 37 after the commencement of the first course of therapy, while the responders in the no cytokine arm started on median day 40.5 (P = 0.082).
The overall antileukaemic response to treatment is presented in Table 4 . There were no differences in the overall response rates between the lenograstim and no cytokine arms, nor any differences in the response after one or two courses. The final complete response rate was 81% (95% CI 69-91) in the lenograstim arm compared to 75% (95% CI 62-85) in the no cytokine arm (P = 0.50).
Similarly, no differences in overall survival were detected between the two groups, with an estimated median potential follow-up time from cytokine randomisation to the study close-out date of 3.6 years ( Figure 3 ). The estimated relative death rate for patients on the lenograstim arm relative to the no cytokine arm was 0.83 (95% CI 0.49-1.40) (P = 0.48).
Discussion
The major finding of this randomised study is that the granulopoietic-stimulating effects of G-CSF were still observed after intensive induction chemotherapy for AML. In the group of AML patients randomised to receive lenograstim, recovery of neutrophils to clinically significant levels (0.1 and 0.5 × 10 9 /l) occurred significantly faster than in the group of patients not receiving cytokine treatment. This was accompanied by a reduction in the need for intravenous antibiotics and a trend to fewer days of fever. No difference in the rate of infections was observed between the two groups, possibly due to the high underlying rate of clinically and microbiologically docu- Table 4 Effects of lenograstim on response rates to induction therapy No Cytokine Lenograstim P n = 59 b n = 54 n % n % mented infection in this group of intensively myelosuppressed patients and the relatively small sample size. Similarly there was no difference in the rate of infective deaths in induction. Studies with larger patient numbers, for example that reported by Heil and colleagues, 18 have also failed to detect a difference in the rate of both bacterial and fungal infections in patients receiving G-CSF compared to placebo, most likely due to the fact that the majority of infections occur during the early phase of neutropenia after completion of induction therapy.
Although there has been a substantial number of randomised and non-randomised studies examining the role of myeloid growth factors in the treatment of AML, almost all the trials carried out on previously untreated patients have been confined to studies involving conventional-dose chemotherapy. Since it is possible that more intensive induction therapy, designed to achieve greater leukaemic cytoreduction, may adversely affect the normal haematopoietic stem cell population, including the response to stimulatory cytokines, we examined whether lenograstim would provide the same degree of stimulation of granulopoiesis after chemotherapy intensified by high-dose cytarabine. Only one other study has addressed this question before. Estey and colleagues 22 compared the value of G-CSF in parallel but non-randomised cohorts of patients treated with high-dose cytarabine and fludarabine. A statistically significant reduction in the recovery of neutrophils to 1.0 × 10 9 /l, from 34 to 21 days, was observed in the G-CSF group, although no differences in infections or in the early death rate during induction therapy were observed.
Estey and colleagues 22 also found no differences in the complete remission rates between the G-CSF and no cytokine groups. We similarly did not find a difference in complete response rate between cytokine and no cytokine groups in our study. A larger patient cohort may have allowed detection of response differences, although this did not emerge from large studies where conventional-dose therapy was used. 14, 18 Although the group of patients randomised to lenograstim did not have a detectable reduction in infections compared to the no cytokine arm, there were material benefits associated with the use of G-CSF in our study. These included a reduction in the days with fever, less usage of intravenous antibiotics, and reduced hospital stay. These practical improvements in outcome are likely to be a consequence of the reduced duration of severe neutropenia, and were also noted in a previous study of G-CSF after standard-dose induction therapy for AML. 18 There have been three reports of cost analyses of adjunct colony-stimulating factors for adult AML in oncology cooperative group trials. 23 Lu et al 24 performed a retrospective economic analysis on all 521 patients enrolled in a randomised placebo controlled trial of filgrastim. They assumed fixed unit costs of hospitalisation (US$900 per day including US$100 for a daily physician visit), i.v. anti-infective therapy (US$200 per day), platelet transfusions (US$300 per day) and filgrastim (US$169 per day), and found that the filgrastim-treated arm had a net cost saving of US$2230 in the first induction course. These costs are quite different to the Australian costs based on the conversion rate of one US dollar to two Australian dollars, applicable at the time of preparation of this report. The daily hospital cost in the Lu study is 2.8 times our cost, the daily cost of i.v. anti-infectives is 4.3 times our cost, but the daily cost of G-CSG is only 1.4 times our cost. If we had calculated our costs using the costs in the Lu study, and ignored oral antibiotics, we would have estimated lenograstim to have a net cost saving of US$758 (A$1516).
Bennett et al 25 used a decision analytic model to estimate the economic costs and benefits of G-CSF in a randomised placebo controlled trial of G-CSF in induction as support for 207 AML patients greater than 55 years of age. The primary source of clinical event probabilities was the in-hospital care with or without an active infection requiring intravenous antibiotics. The median costs per day with and without an active infection were estimated to be US$1840 and US$1370, respectively, giving rise to an estimated cost of US$51 950 for the placebo patients and US$52 070 for the lenograstim patients, a net increase of US$120 for the lenograstim patients. Using the same method of analysis in a study of 88 AML patients Ͼ55 years of age who received GM-CSF or placebo, GM-CSF was estimated to be associated with an increased cost of US$2310. 26 These comparative studies used relatively simple methods of estimating the incremental cost of growth factor use and provided no estimate of the variability in the estimates of the incremental cost. In our study, lenograstim was associated with an estimated increase in cost of A$1494, but the 95% confidence interval was very wide, ranging from a net saving of A$2191 to a net increase of A$5342. Although the results of these costing studies might appear to be inconclusive, it is clear that the incremental cost of cytokines is relatively insignificant in light of other costs.
A further important consequence of the shortened period of neutropenia with lenograstim was that patients were able to proceed with the next course of chemotherapy earlier than those without cytokines. This is of potential significance in that it may have led to an enhancement of the dose intensity of initial treatment for these patients, a factor proven to be important for cure of a number of human cancers. 27, 28 Dose intensification in AML remains a controversial issue, and is the subject of the ALSG M7 trial. The contribution of lenograstim to the delivery of intensified early chemotherapy in AML is however likely to be an important outcome of the present study.
In conclusion, this randomised study demonstrated a highly significant reduction in the duration of severe neutropenia after high-dose induction chemotherapy for AML, resulting in an improvement in a number of clinically important parameters, including the delivery of subsequent courses of therapy. No major adverse effects of the use of G-CSF were observed, and we conclude that this drug may have a supportive role in this setting.
